✦ LIBER ✦

Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients

✍ Scribed by A. P. Anselmo; G. Meloni; E. Cavalieri; A. Proia; R. Maurizi Enrici; D. Funaro; E. Pescarmona; F. Mandelli

Publisher: Springer
Year: 2000
Tongue: English
Weight: 73 KB
Volume: 79
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770050014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2038 Autologous bone marrow transplantat

2038 Autologous bone marrow transplantation following high-dose chemotherapy with or without accelerated hyperfractionated total lymphoid irradiation for patients with refractory or relapsed Hodgkin's disease

✍ Janaki Moni; Joachim Yahalom; Joseph Bertino; James O'Brien; Carol Portlock; Dav 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 96 KB

High-dose therapy with peripheral blood

High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors

✍ K. Neben; S. Hohaus; H. Goldschmidt; G. Egerer; M. T. Voso; A. D. Ho; R. Haas 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 118 KB

High-dose sequential chemotherapy and pe

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma : A multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence

✍ Corrado Tarella; Alessandra Cuttica; Umberto Vitolo; Marina Liberati; Massimo Di 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate in a multicenter setting the feasibility and efficacy of a high‐dose sequential (HDS) chemotherapy regimen that combined intensive debulking and high‐dose therapy (HDT) with peripheral blood progenitor cell (PBPC) autogra

A single, high dose of idarubicin combin

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

✍ Mark A. Weiss; Timothy B. Aliff; Martin S. Tallman; Stanley R. Frankel; Matt E. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Background: The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. one option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense